Morbidity in Patients With Hypertension and Obstructive Sleep Apnea

Conditions

Hypertension, Sleep Apnea, Obstructive

Keywords

continuous positive airway pressure, hypertension, sleep apnea

Brief summary

MORPHEOS is a multicenter, randomized, unblinded study, for patients diagnosed with uncontrolled hypertension and at least one antihypertensive medication. Those patients with significant sleep apnea wil be randomized to CPAP or nasal strips for 6 months.

Geraldo Lorenzi‐Filho, Fernanda C. S. G. Cruz, Daniel B.C. Queiróz, Marcelo Luiz Campos Vieira, Rodrigo Pinto Pedrosa et al. (19 authors)

Annals of the American Thoracic Society2025-01-293 citations

10.1513/annalsats.202407-688oc

The effect of continuous positive airway pressure on blood pressure in patients with obstructive sleep apnea and uncontrolled hypertension - Study design and challenges during the COVID-19 pandemic.

Cruz FCSG, Drager LF, Queiróz DBC, Souza GA, Pedrosa RP, Patriota TLGC, Dórea EL, Vieira MLC, Righi CG, Martinez D, Silva GAD, Silva GV, Pio-Abreu A, Lotufo PA, Benseãor IM, Bortolotto LA, Fuchs FD, Lorenzi-Filho G.

2021-09-032 citations

10.6061/clinics/2021/e2926

Interventions

DEVICECPAP

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

No

Inclusion criteria

* Systolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥ 90 mm Hg * Current treatment with at least 1 antihypertensive drug

Exclusion criteria

* Age \<18 and \>65 years * BMI ≥ 40 kg/m2 * Heart failure, EF \< 45%, acute myocardial infarction, stroke, significant valvular dysfunction * Chronic renal failure (serum creatinine \> 2 mg/dL) * Use of cocaine, amphetamines, alcohol, illicit drugs * Use of sympathomimetics (decongestants, appetite suppressants) * Use of oral contraceptives and chronic use of NSAIDs * Pregnancy * Secondary causes of hypertension (other than sleep apnea)

Design outcomes

Primary

Measure	Time frame
Impact of OSA treatment with CPAP on office, 24-hour, and central blood pressure (co-primary endpoints).	6 months

Secondary

Measure	Time frame	Description
Impact of OSA treatment with CPAP on target-organ damage	6 months	—
Impact of OSA treatment with CPAP on vascular parameters (to be published as a sub-study)	6 months	Pulse wave velocity and carotid intima-media thickness
Impact of OSA treatment with CPAP on hypertensive retinopathy and optic nerve damage (to be published as a sub-study)	6 months	—
Validation of portable sleep monitoring to diagnose OSA (to be published as a sub-study)	6 months	—

Countries

Brazil

Outcome results

None listed